Science - Read it!

July 2021

Targeting the m 6 A RNA modification pathway blocks SARS-CoV-2 and HCoV-OC43 replication

Exciting collaboration with Ian Mohr and Angus Wilson understanding how RNA modifications impact coronavirus biology (

January 2021

Antibody isotype diversity against SARS-CoV-2 is associated with differential serum neutralization capacities

Exciting collaboration throughout NYU investigating the antibody response to SARS-CoV-2. (

December 2020

Mapping the Evolutionary Landscape of Zika virus Infection in Immunocompromised mice.

Awesome collaboration with the Ghedin Lab ( and Cadwell Lab ( studying how Zika virus evolves (

December 2020

An ACE2 Microbody Containing a Single Immunoglobulin Fc Domain Is a Potent Inhibitor of SARS-CoV-2

Collaboration with Ned Laudau's Lab at NYU developing new SARS-CoV-2 antivirals. (

The ACE2-binding interface of SARS-CoV-2 Spike inherently deflects immune recognition

Collaboration with Shohei Koide's Lab at NYU looking at SARS-CoV-2 antibody interactions. (

November 2020

Repurposing FDA-approved drugs for SARS-CoV-2 through an ELISA-based screening for the inhibition of RBD/ACE2 interaction

Collaboration with Chuan-Ju Liu's Lab at NYU screening FDA-approved compounds against SARS-CoV-2. (

October 2020

Chikungunya virus antagonizes cGAS-STING mediated type-I interferon responses by degrading cGAS

Collaboration with the Fernandez-Sesma Lab at Mt. Sinai to understand how CHIKV antagonizes the innate immune response.

June 2020

Distinct New York City Aedes albopictus Mosquito Populations Display Differences in Salivary Gland Protein D7 Diversity and Chikungunya Virus Replication

Maryska characterizes antiviral factors and CHIKV replication and evolution in New York City mosquitoes! (

July 2019

Evolution-driven attenuation of alphaviruses highlights key glycoprotein determinants regulating viral infectivity and dissemination

First Stapleford Lab CHIKV dissemination paper! Gaby, Bruno, and Margarita identify a network of molecular interactions that modulate CHIKV infectivity and dissemination. (

July 2019

Chikungunya virus vaccine candidates with decreased mutational robustness are attenuated in vivo and have compromised transmissibility.

Collaboration with the Vignuzzi lab at Institut Pasteur, Paris, to develop novel vaccine strategies for arboviruses. (

May 2019

Atovaquone Inhibits Arbovirus Replication through the Depletion of Intracellular Nucleotides.

First paper from the Stapleford Lab! Angelica Kottkamp defines the antiviral mechanism of the antiparasitic drug atovaquone. (

June 2018

Chikungunya virus evolution following a large 3'UTR deletion results in host-specific molecular changes in protein-coding regions.

Collaboration with Paul Turner's lab at Yale University to understand the evolution of the chikungunya virus 3'UTR. (